Ganapati Hegde Email and Phone Number
- Accomplished and innovative scientific leader with 15 years of demonstrated success in oncology precision medicine R&D within the biotech industry.- Expertise includes model development, target identification and validation, small (degraders, inhibitors) and large (antibody, ADC) molecule therapeutics development, in vitro and in vivo pharmacology, and the development of translational research/medicine strategies for clinical implementation.- Led a team for patient relevant model development for biomarker discovery, and developed Translational Research/biomarker strategy including indication prioritization/patient segmentation, predictive & pharmacodynamic biomarker discovery and prototype assays development for clinical implementation for multiple portfolio projects with exceptional scientific expertise- Effective manager of teams, projects, and CROs, with a proven ability to collaborate with cross-functional teams to drive project success and advance company portfolios.- Provides mentorship to scientists and team members, fostering career growth and development. - Excels in delivering presentations and business communications across all organizational levels.
Antares Therapeutics
View- Website:
- antaresrx.com
- Employees:
- 93
-
Sr. Director, BiologyAntares TherapeuticsCalifornia, United States
-
Senior Principal ScientistBristol Myers Squibb Dec 2021 - PresentRedwood City, California, United States• Led oncology precision medicine Translational Research Biomarker Group (5 members) & TR sub-teams and developed translational biomarker strategies including potential indication prioritization & patient segmentation, predictive & PD biomarker discovery, and fit-for purpose prototype assays development for clinical implementation for approximately ten early portfolio projects.• Effectively managed collaboration with cross functional teams such as Cancer Biology, Bioinformatics, Translational Medicine, Clinical Development etc., and contributed to core teams as a key member for GO/NO-GO decisions.• Oversaw prototype assay development for clinical implementation within group for MSD-ELISA, nano-string, OLINK and worked with technology groups (IHC, Genomics, FACS & CROs).• Developed human disease relevant models for biomarker discovery, validation and refinement.• Led the Reverse Translation Forum that identified high quality targets and supported around ten portfolio projects to strengthen translational plans. -
Senior Principal ScientistOric Pharmaceuticals Sep 2019 - Dec 2021San Francisco Bay Area• Managed an internal team, four CROs for agreements (SOW)-budget-execution, cross functional team collaboration and led oncology precision medicine projects for target identification & validation, lead discovery/identification & optimization, development of therapeutics, MOA studies, in vitro & in vivo POC, PD and predictive biomarker identification, and indication prioritization & patient segmentation thereby advanced clinical candidate to ORIC portfolio.• Led Translational Medicine efforts for predictive & PD biomarker discovery for GR-inhibitor (ORIC-101) in NSCLC, and worked in multi-disciplinary Clinical Development team and contributed to the design and implementation of translational and clinical biomarker strategy for clinical trial.• Took many additional responsibilities while successfully establishing ORIC from Series A funding to IPO and target to clinic.• Presented the project progress to the Scientific Advisory Board. -
Principal ScientistOric Pharmaceuticals May 2017 - Aug 2019South San Francisco
-
Principal Scientific ResearcherGenentech Nov 2015 - May 2017South San Francisco, Ca, Usa• Led multiple oncology precision medicine projects and successfully advanced clinical candidates for 3 oncology projects that entered into Genentech portfolio.• Developed and characterized approximately six in vitro and in vivo xenograft preclinical models, which were subsequently utilized in about ten projects to innovate therapeutic strategies.• Conducted gene expression profiling, identified potential therapeutic targets, validated them in vitro and in vivo using genetic perturbation (shRNA and CRISPR) and tool compounds, and developed innovative therapeutic strategies.• Developed assays for therapeutics screening, identified lead and backups, lead optimization, demonstrated proof of concept in vitro and in vivo, elucidated mechanisms of action, and conducted PK/PD, efficacy, and exploratory toxicology studies thereby identified clinical candidates.• Conducted translational research and developed biomarker strategies, including mechanistic-based predictive and pharmacodynamic biomarkers/assays, and prioritized potential indications and patient segments. -
Senior Scientific ResearcherGenentech Aug 2008 - Oct 2015South San Francisco, Ca, Usa
-
Postdoctoral Research AssociateUniversity Of Nebraska Medical Center Feb 2003 - Aug 2008Greater Omaha Area• Isolated cancer cells from Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) patients, conducted gene expression profile for biomarker and target identification.• Elucidated the role of hedgehog signaling in the pathogenesis of MCL and CLL, and demonstrated overcoming chemotherapy resistance by targeting of hedgehog signaling as a therapeutic strategy.• Developed therapeutic strategy for the treatment of chemo-resistant MCL by targeting proteasome or hedgehog signaling followed by Adoptive T-cell Transfer in NOD/SCID preclinical model.• Worked in collaboration with Prommune Inc. of Omaha, NE to demonstrate the internalization, processing and presentation of molecular adjuvant based vaccine against cancer by human dendritic cells.• Supervised graduate students, research technologists and summer students.• Reviewer for many journals; Blood, Cancer Research, Clinical Cancer Research etc. -
ScientistShantha Biotechnics Limited,Part Of Sanofi Aventis Group Jan 2003 - Feb 2003Hyderabad Area, India• Led a small team in executing projects focused on developing efficient methods for bulk-scale purification of recombinant therapeutic proteins. -
ScientistJubilant Biosys Nov 2001 - Dec 2002Bangalore Area, India• Led a team of five scientists and collaborated with a multidisciplinary project team, driving team success and ensuring on-time deliverables for global pharma and biotech clients.
Ganapati Hegde Education Details
-
Doctor Of Philosophy (Ph.D.) -
Master Of Science
-
Bachelor Of Science
Frequently Asked Questions about Ganapati Hegde
What company does Ganapati Hegde work for?
Ganapati Hegde works for Antares Therapeutics
What is Ganapati Hegde's role at the current company?
Ganapati Hegde's current role is Sr. Director, Biology.
What schools did Ganapati Hegde attend?
Ganapati Hegde attended University Of Nebraska Medical Center, Karnatak University, Karnatak University, Karnatak University.
Not the Ganapati Hegde you were looking for?
-
Ganapati Hegde
Cincinnati Metropolitan Area1genpact.com -
Ganapati Hegde
United States -
4gmail.com, thomsonreuters.com, tr.com, epiqglobal.com1 +121490XXXXX
-
Ganapati Hegde
Detroit Metropolitan Area
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial